Claris Lifesciences IPO GMP History
Claris Lifesciences IPO has been listed on December 20, 2010 at a listing price of ₹224.4, against the issue price of ₹228 — a loss of ₹3.6 (-1.58%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Claris Lifesciences IPO raised ₹300 Cr. through its IPO at a price band of ₹228 to ₹235 per share, with a lot size of 22 shares. The IPO was open for subscription from 24 Nov 2010 to 02 Dec 2010.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 12 Nov, 3:09 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
Claris Lifesciences IPO dates
Key dates from opening to listing. Today is 15 November.
- Open 24 Nov 2010
- Close 02 Dec 2010
- Allotment 15 Dec 2010
- Refund/credit TBA
- Listing 20 Dec 2010
Claris Lifesciences IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹228 |
|---|---|
| Listing gain / loss | −₹3.6 per share |
| Listing date | 20 Dec, 2010 |
| Actual listing price | ₹224.4 (-1.58%) |
Is Claris Lifesciences IPO GMP reliable?
Grey market premium for Claris Lifesciences IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Claris Lifesciences IPO full review for a fundamentals-based assessment before making any grey market trades.
Claris Lifesciences IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Claris Lifesciences IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Claris Lifesciences IPO
Claris Lifesciences Limited was originally incorporated as Oracle Laboratories Limited on 19 July 1994 as a public limited company. Its promoters are Arjun S. Handa and Sarjan Financial.
It is one of the largest Indian sterile injectables companies, with a presence in 76 countries. Its offering of 128 products is entirely off patent, and most can be injected directly and are used to treat critical illnesses.
Its products cover anaesthesia, critical care, anti infectives, renal care, infusion therapy, enteral and parenteral nutrition and oncology.
The IPO was Rs 300 crore and was entirely fresh issue at Rs 228, the bottom of the Rs 228 to Rs 235 band. The money was for a new injectables plant, a propofol line, an R&D facility and prepaying a term loan.
Frequently asked
What is the GMP of Claris Lifesciences IPO?
The current Grey Market Premium (GMP) of Claris Lifesciences IPO is not yet started or active in the market.
What is the Kostak Price of Claris Lifesciences IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Claris Lifesciences IPO is not available.
What is the Subject to Sauda Price of Claris Lifesciences IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Claris Lifesciences IPO?
Claris Lifesciences IPO listed on December 20, 2010 at ₹224.4, against the issue price of ₹228 — a loss of -1.58%.
How did the GMP of Claris Lifesciences IPO trend before listing?
The GMP of Claris Lifesciences IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore Claris Lifesciences IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
